Abstract P4-01-23: Potential prognostic Value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer

Résumé fourni par la source

Abstract Background: HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio is associated with prognosis in patients with HER2-positive non-metastatic BC. Methods: 267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed. Results: The median follow-up time was 10.3 years (interquartile range: 9.4-10.8 years). HER2/CEP17 ratio of > 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of ≤ 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unclear, and so was in the patients who did not receive trastuzumab (all p > 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, p = 0.02), but there was no difference in OS (p = 0.30) in patients receiving trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive have worse DFS than HER2 normal-positive patients (HR = 3.71; p < 0.01). Conclusion: For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict the survival time. However, our study supports that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients. Citation Format: Fangchao Zheng, Feng Du, Zixuan Yang, Xue Wan, Jian Yue, Yun Ling, Peng Yuan. Potential prognostic Value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P4-01-23.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.